Clinical trial
Efficacy and Safety of Tiotropium and Salmeterol in Moderate Persistent Asthma…
NCT00350207 · Boehringer Ingelheim, Industry · Completed
Key facts
| NCT number | NCT00350207 |
|---|---|
| Title | Efficacy and Safety of Tiotropium and Salmeterol in Moderate Persistent Asthma Patients Homozygous for B16-Arg/Arg |
| Official title | A 16-week Randomised, Placebo-controlled, Double-blind, Double-dummy, Parallel-group Study Comparing the Efficacy and Safety of Tiotropium Inhalation Solution Delivered by the Respimat Inhaler (2 Actuations of 2.5 Mcg Once Daily) With That of Salmeterol From the Hydrofluoroalkane Metered Dose… |
| Lead sponsor | Boehringer Ingelheim, Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Asthma |
| Intervention type | Drug |
| Interventions | Tiotropium bromide, Placebo, Salmeterol xinafoate |
| Enrollment | 388 |
| Start date | Jul 1, 2006 |
| Primary completion | Sep 1, 2008 |
| First posted | Jul 10, 2006 |
| Last update posted | Dec 24, 2013 |
| Countries | Austria, Belgium, Denmark, Finland, France, Germany, Greece, Italy, Russia, Slovakia, South Africa, Spain and 2 more |
At a glance
- 100–999 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: